Drug Delivery News and Research RSS Feed - Drug Delivery News and Research

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.
Gerresheimer substantially increases earnings in second quarter of financial year 2014

Gerresheimer substantially increases earnings in second quarter of financial year 2014

Gerresheimer AG substantially increased earnings in the second quarter of financial year 2014."High-quality packaging for drugs and products enabling safe and easy self-medication continues to be increasingly in demand worldwide. [More]
Personalized antibiotic therapy can help fight antibiotic-resistant infections

Personalized antibiotic therapy can help fight antibiotic-resistant infections

The Centers for Disease Control and Prevention warned last fall that the U.S. faces "potentially catastrophic consequences" if it doesn't act quickly to combat the growing threat of antibiotic-resistant infections, which kill about 23,000 Americans a year. [More]
EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor. [More]
Scientists use femtosecond lasers to tackle Parkinson's disease

Scientists use femtosecond lasers to tackle Parkinson's disease

Scientists are combining physics and neurobiology to tackle Parkinson's disease. The Okinawa Institute of Science and Technology Graduate University's Femtosecond Spectroscopy Unit and Neurobiology Research Unit, along with collaborators at the University of Otago, New Zealand are using lasers, nanotechnology and neuroscience to develop a new, versatile drug delivery system. [More]
Adding MM-398 to standard treatment improves survival in metastatic pancreatic cancer patients

Adding MM-398 to standard treatment improves survival in metastatic pancreatic cancer patients

Adding the novel MM-398 to standard treatment for metastatic pancreatic cancer patients who have already received gemcitabine improves survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. [More]
Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Like all drugs, antibiotics can have side-effects when administered to people. The most common (and often benign) side effect people experience when taking antibiotics is “associated diarrhea”. This illustrates the fact that antibiotics have an impact on the intestine! [More]
Study on digestion of milk could lead to development of new formulas for premature babies

Study on digestion of milk could lead to development of new formulas for premature babies

A new study on the digestion of milk could lead to the development of new formulas for premature babies, weight loss drinks and potentially new drug delivery systems. [More]
Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. [More]
NCL collaborates with PeptiMed to evaluate safety and efficacy of nanocomplex materials

NCL collaborates with PeptiMed to evaluate safety and efficacy of nanocomplex materials

PeptiMed announced today that under a Material Transfer Agreement it will collaborate with the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL), located at the Frederick National Laboratory of Cancer Research in Frederick, MD. [More]
Affordable Care Act to have significant impact on patients with diabetes

Affordable Care Act to have significant impact on patients with diabetes

The Affordable Care Act (ACA, also known as Obamacare) is dramatically changing health care delivery in the U.S. Specific parts of the new law, which will be phased in through 2020, will have a significant impact on patients with diabetes and prediabetes, as explored in a comprehensive Review article published in Diabetes Technology & Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
Arrowhead Research joins with broad-market Russell 3000 Index

Arrowhead Research joins with broad-market Russell 3000 Index

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, is set to join the broad-market Russell 3000 Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes. [More]

Double Emulsion System released by Dolomite

Microfluidic products expert Dolomite have released their Double Emulsion System for creating micron sized emulsion droplets that contain still smaller droplets inside. It enables unrivalled reproducibility and selectivity of droplet size of both outer and inner phases with either oil-in-water-in-oil or water-in-oil-in-water droplets. The Double Emulsion System is highly beneficial to applications in the food industry, in pharmaceuticals and cosmetics that use double emulsions as delivery vehicles or encapsulation solutions for various active ingredients, or more generally in paints and coatings. [More]
Investigators isolate protein that is responsible for fungus' ability to cross blood-brain barrier

Investigators isolate protein that is responsible for fungus' ability to cross blood-brain barrier

In a remarkable series of experiments on a fungus that causes cryptococcal meningitis, a deadly infection of the membranes that cover the spinal cord and brain, investigators at UC Davis have isolated a protein that appears to be responsible for the fungus' ability to cross from the bloodstream into the brain. [More]
RBCC's injectable technology poised to improve use of addiction treatment drug

RBCC's injectable technology poised to improve use of addiction treatment drug

Rainbow Coral Corp. received a boost recently when researchers reported that a medication that could help tens of thousands of alcoholics quit drinking are underused. [More]

InSite and Senju collaborate to develop and market azithromycin ophthalmic solution using DuraSite

InSite Vision Incorporated and Senju Pharmaceutical Co., Ltd. today announced that they have entered into a collaboration and license agreement to develop and market InSite's azithromycin ophthalmic solution using DuraSite® including AzaSite® 1% and AzaSite XtraTM 2% ocular antibiotics in Japan. Senju has agreed to pay InSite an upfront license fee, additional development milestones fees, and a percentage royalty on net sales. [More]
BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences International, Inc. received approval of the New Drug Application (NDA) for BUNAVAIL™ (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA). [More]
Co-founder of Avidity Nanomedicines to receive 2014 Prince of Asturias Award

Co-founder of Avidity Nanomedicines to receive 2014 Prince of Asturias Award

Avidity NanoMedicines LLC, a biopharmaceutical company pioneering a breakthrough approach to the targeted delivery of nucleic acid-based medicines, announced today that its scientific co-founder, Mark E. Davis, Ph.D., will receive the 2014 Prince of Asturias Award for Technical and Scientific Research. [More]
Scientists design nanoparticle to target tumor cells

Scientists design nanoparticle to target tumor cells

Scientists at UC Santa Barbara have designed a nanoparticle that has a couple of unique - and important - properties. [More]
Rice, MD Anderson researchers refine technique for attacking hard-to-reach tumors

Rice, MD Anderson researchers refine technique for attacking hard-to-reach tumors

Short, customized carbon nanotubes have the potential to deliver drugs to pancreatic cancer cells and destroy them from within, according to researchers at Rice University and the University of Texas MD Anderson Cancer Center. [More]
New nanomedicine allows glaucoma patients to do away with daily eye drops

New nanomedicine allows glaucoma patients to do away with daily eye drops

Scientists from Nanyang Technological University (NTU) and the Singapore Eye Research Institute (SERI) have jointly developed a new nanomedicine that will allow glaucoma patients to do away with daily eye drops. [More]